Better Times Ahead For Esperion Therapeutics Inc. (NASDAQ: ESPR)?
Esperion Therapeutics Inc. (ESPR) concluded trading on Wednesday at a closing price of $2.12, with 4.63 million shares of worth about $9.81 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 15.22% during that period and on October 16, 2024 the price saw a […]
Better Times Ahead For Esperion Therapeutics Inc. (NASDAQ: ESPR)?
Esperion Therapeutics Inc. (ESPR) concluded trading on Wednesday at a closing price of $1.93, with 4.01 million shares of worth about $7.73 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -23.41% during that period and on October 09, 2024 the price saw a […]
Set Your Sights On Esperion Therapeutics Inc. (NASDAQ: ESPR)’S Upside Potential
Esperion Therapeutics Inc. (ESPR) concluded trading on Wednesday at a closing price of $1.82, with 6.86 million shares of worth about $12.48 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -41.67% during that period and on October 02, 2024 the price saw a […]
Institutional Exposure To Esperion Therapeutics Inc. (ESPR)
Esperion Therapeutics Inc. (ESPR) concluded trading on Wednesday at a closing price of $2.61, with 4.62 million shares of worth about $12.07 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 76.35% during that period and on Wednesday the price saw a loss of […]
Esperion Therapeutics Inc. (NASDAQ: ESPR) Stock In Prove Me State
Esperion Therapeutics Inc. (ESPR) concluded trading on Thursday at a closing price of $2.66, with 2.99 million shares of worth about $7.95 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 73.86% during that period and on Thursday the price saw a gain of […]
Do Esperion Therapeutics Inc. (NASDAQ: ESPR) Fit In A Value Investing Philosophy?
Currently, there are 170.42M common shares owned by the public and among those 169.06M shares have been available to trade. Insiders at the company have transacted a total of 31 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 17 of these insider trades were purchases, […]
Growth Story Still Intact For Esperion Therapeutics Inc. (ESPR)
Esperion Therapeutics Inc. (ESPR) concluded trading on Wednesday at a closing price of $2.14, with 6.62 million shares of worth about $14.18 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 26.63% during that period and on Wednesday, January 31 the price saw a […]
Esperion Therapeutics Inc. (NASDAQ: ESPR): Hunting Genuine Value In Market Debris
Two Seas Capital LP recently announced the acquisition of new stake in Esperion Therapeutics Inc. (NASDAQ:ESPR). The institutional investor has increased its shareholding in the Healthcare company by 160.79% to 7.67 million shares with purchase of 4.73 million shares. This fresh investment now brings its stake to 6.75% valued currently at $22.94 million. In addition, […]
Do Esperion Therapeutics Inc. (NASDAQ: ESPR) Fit In A Value Investing Philosophy?
Two Seas Capital LP recently announced the acquisition of new stake in Esperion Therapeutics Inc. (NASDAQ:ESPR). The institutional investor has increased its shareholding in the Healthcare company by 160.79% to 7.67 million shares with purchase of 4.73 million shares. This fresh investment now brings its stake to 6.75% valued currently at $10.2 million. In addition, […]
Esperion Therapeutics Inc. (NASDAQ: ESPR) Stock In Prove Me State
Two Seas Capital LP has recently announced that it has increased stake in Esperion Therapeutics Inc. (NASDAQ:ESPR) by 160.79%. After grabbing 7.67 million shares, the institutional investor is now in possession of 4.73 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 6.75% having worth around $10.2 million. […]
